Stay updated with breaking news from Phore Limited. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Additional funding will be used to explore novel biology around the MMR pathway and accelerate progression of the lead program into candidate selectionLONDON, May 22, 2024 /PRNewswire/ -- NeoPhore
/PRNewswire/ -- NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that it has signed a strategic collaboration agreement...
A round-up of the latest news from the Life Science industry; including news from the Pharmaceutical, Clinical Research, Biotechnology and Medical Device sectors from 25th-29th July ...
CAMBRIDGE, England, July 28, 2022 /PRNewswire/ -- NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that it has entered a three-year research collaboration
Share this article Round led by Claris Ventures with 2Invest, 3B Future Health Fund and Astellas Venture Management CAMBRIDGE, England, March 9, 2021 /PRNewswire/ -- NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces the close of a £15.2m (US $21m) Series B round. The syndicate was led by Claris Ventures and included 2Invest, 3B Future Health Fund and Astellas Venture Management alongside founding investor the CRT Pioneer Fund. NeoPhore is focused on the discovery and development of novel first-in-class small molecule drugs targeting the DNA mismatch r...